Welcome to the e-CCO Library Archive!
P451
The efficacy of infliximab in tacrolomus non-responder with ulcerative colitis
T. Miyazaki*, N. Hida, T. Sato, M. Kawai, K. Kamikozuru, T. Takagawa, Y. Yokoyama, M. Iimuro, K. Hori, S. Nakamura
Hyogo College of Medicine, Division of Internal Medicine Department of Inflammatory Bowel Disease, Nishinomiya, Japan
P452
Safety and efficacy of infliximab biosimilar (Remsima©) in Crohn’s disease patients in clinical practice: results after 6 months of treatment
M. F. Guerra Veloz*1, F. Argüelles Arias1, R. Perea Amarillo1, L. Castro Laria1, M. B. Maldonado Pérez1, A. Benítez Roldán1, V. Merino2, G. Ramirez2, A. Vilches Arenas3, A. Caunedo Álvarez1
1Unidad de Gestión Clínica de Aparato Digestivo Hospital Universitario Virgen Macarena, Seville, Spain, 2Unidad de Farmacia Hospital Universitario Virgen Macarena, Seville, Spain, 3Universidad de Sevilla, Medicina preventiva y salud pública, Seville, Spain
P453
Insufficient vaccination and inadequate immunisation rates amongst Korean patients with inflammatory bowel diseases
H. H. Ryu1, H.-S. Lee2, B. D. Ye*3, N. Y. Kim4, E. J. Youn3, J. Y. Park3, E. Kang3, S. W. Hwang1, S. H. Park3, D.-H. Yang1, K.-J. Kim3, J.-S. Byeon1, S.-J. Myung1, S.-K. Yang3
1University of Ulsan College of Medicine, Asan Medical Centre, Gastroenterology, Seoul, South Korea, 2University of Ulsan College of Medicine, Asan Medical Centre, Health Screening and Promotion Centre, Seoul, South Korea, 3University of Ulsan College of Medicine, Asan Medical Centre, Gastroenterology, Inflammatory Bowel Disease Centre, Seoul, South Korea, 4University of Ulsan College of Medicine, Asan Medical Centre, Clinical Epidemiology and Biostatistics, Seoul, South Korea
P454
Combo-therapy in infliximab-resistant inflammatory bowel disease patients: data from a tertiary referral centre
S. Renna*, G. Rizzuto, E. Orlando, M. Affronti, M. Cottone, A. Orlando
‘Villa Sofia-Cervello’ Hospital, Division of Internal Medicine, Palermo, Italy
P455
The effect of concurrent HIV-1 infection on the management of patients with inflammatory bowel disease
T. H. Ho, R. Fausel, J. Torres, J. J. Yang, T. H. Swartz, J. A. Aberg, J.-F. Colombel, S. Mehandru*
Icahn School of Medicine at Mount Sinai, New York, New York, United States
P456
Efficacy and safety of TNF antagonist for the treatment of internal fistulising Crohn’s disease
A. Huguet1, A.-L. Mallet1, V. Desfourneaux1, L. Siproudhis1, J.-F. Bretagne2, G. Bouguen*2
1Université Rennes 1 & CHU Pontchaillou Rennes, Service de chirurgie digestive, Rennes, France, 2Université Rennes 1 & CHU Pontchaillou Rennes, Service des Maladies de l’Appareil Digestif, Rennes, France
P457
Complications and disease recurrence after primary ileocecal resection in paediatric Crohn’s disease: a multicentre cohort analysis
K. Diederen*1, L. de Ridder2, P. van Rheenen3, V. Wolters4, L. Mearin5, G. Damen6, T. de Meij7, H. van Wering8, L. Tseng1, M. Oomen9, J. de Jong9, M. Benninga1, A. Kindermann1
1Academic Medical Centre, Department of Paediatric Gastroenterology and Nutrition, Amsterdam, Netherlands, 2Erasmus MC-Sophia Children’s Hospital, Department of Paediatric Gastroenterology, Rotterdam, Netherlands, 3University Medical Centre Groningen, Department of Paediatric Gastroenterology, Groningen, Netherlands, 4University Medical Centre Utrecht, Department of Paediatric Gastroenterology, Utrecht, Netherlands, 5Leids Universitair Medisch Centrum, Department of Paediatrics, Leiden, Netherlands, 6Radboud University Medical Centre, Department of Paediatric Gastroenterology, Nijmegen, Netherlands, 7VU University Medical Centre, Department of Paediatric Gastroenterology, Amsterdam, Netherlands, 8Amphia Hospital, Department of Paediatrics, Breda, Netherlands, 9Academic Medical Centre, Department of Paediatric Surgery, Amsterdam, Netherlands
P458
Multidisciplinary working when developing the UK inflammatory bowel disease standards and IBD audit
A. St. Clair Jones*1, S. Murray2
1Brighton and Sussex University Hospitals NHS Trust, Pharmacy, Brighton, United Kingdom, 2Royal College of Physicians, Clinical Effectiveness and Evaluation Unit, London, United Kingdom
P459
Risk of relapse after azathioprine discontinuation in inflammatory bowel disease patients in maintained remission
M. Iborra*1, B. Navarro1, X. Cortes2, M. Boscá3, T. Blazquez1, J. Herreras1, G. Trejo3, B. Beltrán1, P. Nos1
1Hospital Universitari i Politecnic La Fe, Gastroenterology, Valencia, Spain, 2Hospital de Sagunto, Gastroenterology, Sagunto, Spain, 3Hospital Clínic Valencia, Gastroenterology, Valencia, Spain
P460
Effect of fertility treatment on inflammatory bowel disease outcomes
M. Bejaoui*, C. Landman, J. Kirchgesner, A. Bourrier, I. Nion-Larmurier, H. Sokol, L. Beaugerie, J. Cosnes, P. Seksik
Saint Antoine Hospital, Gastroenterology & Nutrition, Paris, France
P461
Clinical benefit of adalimumab after surgery in the treatment of complex perianal Crohn’s disease: a tertiary referral centre experience
G. Solina*1, S. Renna2, E. Orlando2, M. Affronti2, M. Cottone2, A. Orlando2
1’Villa Sofia-V. Cervello’ Hospital, Division of Surgery, Palermo, Italy, 2’Villa Sofia-Cervello’ Hospital, Division of Internal Medicine, Palermo, Italy
P462
Adalimumab improves treatment satisfaction with medication and work productivity amongst patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA
S. Travis*1, B. Feagan2, L. Peyrin-Biroulet3, R. Panaccione4, S. Danese5, A. Lazar6, A. Robinson7, J. Petersson7, M. Bereswill6, M. Skup7, N. Chen7, S. Wang7, R. Thakkar7, J. Chao7
1Oxford University Hospitals, Oxford, United Kingdom, 2Robarts Research Institute, Ontario, Canada, 3University Hospital of Nancy, Les Nancy, France, 4University of Calgary, Medicine, Calgary, Canada, 5Istituto Clinico Humanitas, Milan, Italy, 6AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany, 7AbbVie Inc, North Chicago, Illinois, United States
P463
Combination therapy of fresh faecal microbial transplantation and antibiotics for ulcerative colitis
D. Ishikawa*, T. Osada, K. Haga, T. Kodani, T. Shibuya, S. Watanabe
Juntendo University, Department of Gastroenterology, Tokyo, Japan
P464
Assessing medication adherence in patients with inflammatory bowel disease: what do we choose, self-adherence scales or pharmacy rates?
M. L. De Castro*1, L. Sanromán1, A. Martín2, N. Martínez2, M. Figueira1, V. Hernández1, J. R. Pineda1, J. Martínez-Cadilla1, S. Pereira1, V. Del Campo3, J.-I. Rodríguez-Prada1
1Hospital Alvaro Cunqueiro. Complexo Hospitalario Universitario de Vigo. CHUVI, Gastroenterology, Vigo, Spain, 2Hospital Alvaro Cunqueiro. Complexo Hospitalario Universitario de Vigo. CHUVI, Hospital Pharmacy, Vigo, Spain, 3Hospital Alvaro Cunqueiro. Complexo Hospitalario Universitario de Vigo. CHUVI, Epidemiology, Vigo, Spain
P465
Indication-specific feasibility assessment of a placebo-controlled randomised mesalazine withdrawal study for paediatric patients with ulcerative colitis
N. Croft1, W. Faubion2, D. Tierens3, J. Dewulf3, D. Bwirire3, D. Stefani-Hunyady4, F. Cataldi*5
1Blizard Institute, Barts and The London School of Medicine and Dentistry, Centre for Immunobiology, London, United Kingdom, 2Mayo Clinic, Department of Gastroenterology and Hepatology, Rochester, Minnesota, United States, 3Shire, Brussels, Belgium, 4Shire, Lexington, Massachusetts, United States, 5Shire, Gastroenterology, Lexington, Massachusetts, United States
P466
Relapse rates of inflammatory bowel disease patients in deep and clinical remission after discontinuing anti-tumour necrosis factor alpha therapy: a prospective single-centre open-label study
T. Hlavaty*, A. Krajcovicova, J. Letkovsky, I. Sturdik, T. Koller, J. Toth, M. Huorka
Comenius University, Faculty of Medicine and University Hospital Bratislava, Fifth Department of Internal Medicine, Bratislava, Slovakia
P467
The validation of the Crohn’s and Ulcerative Colitis Questionnaire–12 Plus (CUCQ-12 plus): a short quality-of-life measure for inflammatory bowel disease
S. Shwana*1, L. Alrubaiy1, H. Hutchings2, J. Williams2, A. Protheroe3, K. Mortier4
1Prince Charles Hospital, Gastroenterology, Merthyr Tydfil, United Kingdom, 2College of Medicine, Swansea University, Swansea, United Kingdom, 3Royal College of Physicians,, London, United Kingdom, 4Royal College of Physicians, London, United Arab Emirates
P468
Long-term efficacy and safety of thiopurine in biologic-naïve Japanese patients with ulcerative colitis: a multicentre retrospective study
T. Takagi*1, M. Matsuura2, S. Yamada2, S. Bamba3, Y. Hotta1, K. Uchiyama1, Y. Naito1, H. Nakase2, A. Andoh3, T. Kawamura4, S. Katsushima5, T. Kusaka6, H. Obata7, T. Kogawa8
1Kyoto Prefectural University of Medicine, Molecular Gastroenterology and Hepatology, Kyoto, Japan, 2Kyoto University Hospital, Department of Gastroenterology and Hepatology, Kyoto, Japan, 3Shiga University of Medical Science, Department of Medicine, Otsu, Japan, 4Kyoto Second Red Cross Hospital, Kyoto, Japan, 5National Hospital Organisation Kyoto Medical Centre, Kyoto, Japan, 6Kyoto Katsura Hospital, Kyoto, Japan, 7Obata Medical Clinic, Kyoto, Japan, 8Kogawa Internal Medicine Clinic, Internal Medicine Clinic, Kyoto, Japan
P469
Changes in peripheral blood lymphocyte subsets induced by azathioprine in Crohn’s disease patients
A. Labidi*, M. Fekih, N. Ben Mustapha, S. Ben Amor, M. Serghini, L. Kallel, J. Boubaker, A. Filali
La Rabta University Hospital, Gastroenterology, Tunis, Tunisia
P470
Early change in faecal calprotectin during anti-TNFα initiation is strongly predictive of outcome in Crohn’s disease
P. Pavlidis*, G. Chung- Faye, P. Dubois, I. Bjarnason, B. H. Hayee
King’s College Hospital, Department of Gastroenterology, London, United Kingdom